Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹112 Cr
Revenue (TTM)
₹128 Cr
Net Profit (TTM)
₹2 Cr
ROE
0.7 %
ROCE
1 %
P/E Ratio
61.4
P/B Ratio
2.3
Industry P/E
27.55
EV/EBITDA
45
Div. Yield
0 %
Debt to Equity
0
Book Value
₹23.3
EPS
₹1.2
Face value
10
Shares outstanding
21,085,000
CFO
₹-12.55 Cr
EBITDA
₹-7.43 Cr
Net Profit
₹-6.41 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Novelix Pharmaceuticals
| -15.0 | -5.0 | -12.4 | 99.9 | 80.1 | 52.0 | 21.2 |
|
BSE Healthcare
| -3.1 | -3.4 | -6.0 | 7.2 | 23.7 | 13.7 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Novelix Pharmaceuticals
| 158.6 | 104.8 | 8.7 | 54.5 | 8.4 | 118.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Novelix Pharmaceuticals
|
53.2 | 112.2 | 128.0 | 1.8 | 1.8 | 8.5 | 61.4 | 2.3 |
| 2,709.0 | 33,854.4 | 5,201.6 | 1,014.6 | 22.9 | 25 | 33.4 | 7.4 | |
| 7,889.5 | 19,727.4 | 2,177.5 | 200.9 | 11.3 | 26.5 | 98.2 | 23.7 | |
| 1,660.3 | 12,619.8 | 2,089.5 | 622.0 | 31.3 | 20.4 | 20.6 | 3.8 | |
| 1,554.7 | 9,474.6 | 1,196.4 | 149.4 | -- | 27.5 | 63.4 | 13.5 | |
| 1,350.0 | 18,701.9 | 3,078.2 | 469.4 | 26.4 | 14.9 | 43.3 | 5.2 | |
| 1,942.5 | 31,235.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.4 | 7.8 | |
| 4,835.7 | 22,092.5 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.9 | 5.5 | |
| 4,843.6 | 8,030.0 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.4 | 11.5 | |
| 964.4 | 8,914.0 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.4 | 3.0 |
No Review & Analysis are available.
Other financial service activities, except insurance and pension funding activities
Incorporated
1994
Chairman
--
Managing Director
--
Headquarters
Hyderabad, Telangana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Novelix Pharmaceuticals Ltd is ₹53.00 (BSE) as of 08-Apr-2026 IST. Novelix Pharmaceuticals Ltd has given a return of 80.15% in the last 3 years.
The P/E ratio of Novelix Pharmaceuticals Ltd is 61.43 times as on 08-Apr-2026, a 123 premium to its peers’ median range of 27.55 times.
The P/B ratio of Novelix Pharmaceuticals Ltd is 2.28 times as on 08-Apr-2026, a 50 discount to its peers’ median range of 4.52 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
313.43
|
1.51
|
|
2024
|
1,332.56
|
1.89
|
|
2023
|
0.00
|
1.01
|
|
2022
|
0.00
|
0.97
|
|
2021
|
0.00
|
0.80
|
The 52-week high and low of Novelix Pharmaceuticals Ltd are Rs 70.16 and Rs 26.61 as of 09-Apr-2026.
Novelix Pharmaceuticals Ltd has a market capitalisation of ₹ 112 Cr as on 08-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Novelix Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹2.72
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.